Answers are grounded in this paper and cite their sources.
This novel theranostic platform improves T2 MRI contrast and enhances ROS-mediated therapy in triple-negative breast cancer, suggesting targeted treatment potential.
Triple-negative breast cancer is one of the most aggressive and treatment-resistant malignancies. Curcumin–Fe 3 O 4 ZIF-8 NPs provide pH-responsive therapy of TNBC, improved T 2 contrast, tumor-selective curcumin release and ROS-mediated cell death.
No takes yet. Share an insight, caveat, or question.
Rahmani et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: